Antibiotic drug Nitrofurantoin (AMCo, Morningside Healthcare, Morningside Pharmaceuticals and Alliance Healthcare) (50507)
Antibiotic drug Nitrofurantoin (AMCo, Morningside Healthcare, Morningside Pharmaceuticals and Alliance Healthcare) (50507)

The following Competition guidance note provides comprehensive and up to date legal information covering:

  • Antibiotic drug Nitrofurantoin (AMCo, Morningside Healthcare, Morningside Pharmaceuticals and Alliance Healthcare) (50507)
  • Case facts
  • Timeline
  • Commentary
  • Related cases

CASE HUB

See further, timeline ,commentary and related cases.

Case facts

Outline CMA Article 101 TFEU/Chapter I investigation into AMCo (now Advanz Pharma Services (UK) Limited), Morningside Healthcare Limited, Morningside Pharmaceuticals Limited and Alliance Healthcare (Distribution) Limited in relation to an alleged breach of competition law concerning the supply of the antibiotic drug Nitrofurantoin.

Latest developments On 25 July 2019, the CMA issued a statement of objections to AMCo (now Advanz Pharma Services (UK) Limited), Morningside Healthcare Limited, Morningside Pharmaceuticals Limited and Alliance Healthcare (Distribution) Limited.

Parties Advanz Pharma Services (UK) Limited (Advanz): Advanz is a wholly-owned subsidiary of Mercury Pharma Group Limited, which is incorporated in the UK. It is principally engaged in the provision of support services on behalf of the group headed by Concordia International Corp. (formerly Concordia Healthcare Corp).

Mercury Pharma Group Limited (Mercury): Mercury is a wholly-owned subsidiary of Concordia Holdings (UK) Limited